215 related articles for article (PubMed ID: 23337287)
1. Development of a universal CTL-based vaccine for influenza.
Cargnelutti DE; Sánchez MV; Mattion NM; Scodeller EA
Bioengineered; 2013; 4(6):374-8. PubMed ID: 23337287
[TBL] [Abstract][Full Text] [Related]
2. Heterosubtypic immunity against human influenza A viruses, including recently emerged avian H5 and H9 viruses, induced by FLU-ISCOM vaccine in mice requires both cytotoxic T-lymphocyte and macrophage function.
Sambhara S; Kurichh A; Miranda R; Tumpey T; Rowe T; Renshaw M; Arpino R; Tamane A; Kandil A; James O; Underdown B; Klein M; Katz J; Burt D
Cell Immunol; 2001 Aug; 211(2):143-53. PubMed ID: 11591118
[TBL] [Abstract][Full Text] [Related]
3. Induction of protective class I MHC-restricted CTL in mice by a recombinant influenza vaccine in aluminium hydroxide adjuvant.
Dillon SB; Demuth SG; Schneider MA; Weston CB; Jones CS; Young JF; Scott M; Bhatnaghar PK; LoCastro S; Hanna N
Vaccine; 1992; 10(5):309-18. PubMed ID: 1349448
[TBL] [Abstract][Full Text] [Related]
4. Conserved epitopes of influenza A virus inducing protective immunity and their prospects for universal vaccine development.
Staneková Z; Varečková E
Virol J; 2010 Nov; 7():351. PubMed ID: 21118546
[TBL] [Abstract][Full Text] [Related]
5. Effective Respiratory CD8 T-Cell Immunity to Influenza Virus Induced by Intranasal Carbomer-Lecithin-Adjuvanted Non-replicating Vaccines.
Gasper DJ; Neldner B; Plisch EH; Rustom H; Carrow E; Imai H; Kawaoka Y; Suresh M
PLoS Pathog; 2016 Dec; 12(12):e1006064. PubMed ID: 27997610
[TBL] [Abstract][Full Text] [Related]
6. Intranasal administration of a synthetic peptide vaccine encapsulated in liposome together with an anti-CD40 antibody induces protective immunity against influenza A virus in mice.
Ninomiya A; Ogasawara K; Kajino K; Takada A; Kida H
Vaccine; 2002 Aug; 20(25-26):3123-9. PubMed ID: 12163263
[TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity of a recombinant protein influenza A vaccine in adult human volunteers and protective efficacy against wild-type H1N1 virus challenge.
Fries LF; Dillon SB; Hildreth JE; Karron RA; Funkhouser AW; Friedman CJ; Jones CS; Culleton VG; Clements ML
J Infect Dis; 1993 Mar; 167(3):593-601. PubMed ID: 8440931
[TBL] [Abstract][Full Text] [Related]
8. Cytotoxic T lymphocyte responses to a liposome-adjuvanted influenza A virus vaccine in the elderly.
Powers DC; Manning MC; Hanscome PJ; Pietrobon PJ
J Infect Dis; 1995 Oct; 172(4):1103-7. PubMed ID: 7561189
[TBL] [Abstract][Full Text] [Related]
9. Chimeric SV40 virus-like particles induce specific cytotoxicity and protective immunity against influenza A virus without the need of adjuvants.
Kawano M; Morikawa K; Suda T; Ohno N; Matsushita S; Akatsuka T; Handa H; Matsui M
Virology; 2014 Jan; 448():159-67. PubMed ID: 24314646
[TBL] [Abstract][Full Text] [Related]
10. Cross-protective peptide vaccine against influenza A viruses developed in HLA-A*2402 human immunity model.
Ichihashi T; Yoshida R; Sugimoto C; Takada A; Kajino K
PLoS One; 2011; 6(9):e24626. PubMed ID: 21949735
[TBL] [Abstract][Full Text] [Related]
11. Prior population immunity reduces the expected impact of CTL-inducing vaccines for pandemic influenza control.
Bolton KJ; McCaw JM; Brown L; Jackson D; Kedzierska K; McVernon J
PLoS One; 2015; 10(3):e0120138. PubMed ID: 25811654
[TBL] [Abstract][Full Text] [Related]
12. Vaccination with Recombinant Parainfluenza Virus 5 Expressing Neuraminidase Protects against Homologous and Heterologous Influenza Virus Challenge.
Mooney AJ; Gabbard JD; Li Z; Dlugolenski DA; Johnson SK; Tripp RA; He B; Tompkins SM
J Virol; 2017 Dec; 91(23):. PubMed ID: 28931689
[TBL] [Abstract][Full Text] [Related]
13. Cytotoxic T lymphocyte responses of infants after natural infection or immunization with live cold-recombinant or inactivated influenza A virus vaccine.
Mbawuike IN; Piedra PA; Cate TR; Couch RB
J Med Virol; 1996 Oct; 50(2):105-11. PubMed ID: 8915874
[TBL] [Abstract][Full Text] [Related]
14. A CTL-based liposomal vaccine capable of inducing protection against heterosubtypic influenza viruses in HLA-A*0201 transgenic mice.
Matsui M; Kohyama S; Suda T; Yokoyama S; Mori M; Kobayashi A; Taneichi M; Uchida T
Biochem Biophys Res Commun; 2010 Jan; 391(3):1494-9. PubMed ID: 20060099
[TBL] [Abstract][Full Text] [Related]
15. DNA immunization of newborn mice with a plasmid-expressing nucleoprotein of influenza virus.
Bot A; Bot S; Garcia-Sastre A; Bona C
Viral Immunol; 1996; 9(4):207-10. PubMed ID: 8978016
[TBL] [Abstract][Full Text] [Related]
16. In contrast to conventional inactivated influenza vaccines, 4xM2e.HSP70c fusion protein fully protected mice against lethal dose of H1, H3 and H9 influenza A isolates circulating in Iran.
Ebrahimi SM; Dabaghian M; Tebianian M; Jazi MH
Virology; 2012 Aug; 430(1):63-72. PubMed ID: 22595444
[TBL] [Abstract][Full Text] [Related]
17. Development of a cytotoxic T-lymphocyte-based, broadly protective influenza vaccine.
Uchida T
Microbiol Immunol; 2011 Jan; 55(1):19-27. PubMed ID: 21175770
[TBL] [Abstract][Full Text] [Related]
18. Novel Platforms for the Development of a Universal Influenza Vaccine.
Kumar A; Meldgaard TS; Bertholet S
Front Immunol; 2018; 9():600. PubMed ID: 29628926
[TBL] [Abstract][Full Text] [Related]
19. Prospects for an influenza vaccine that induces cross-protective cytotoxic T lymphocytes.
Brown LE; Kelso A
Immunol Cell Biol; 2009; 87(4):300-8. PubMed ID: 19308073
[TBL] [Abstract][Full Text] [Related]
20. Influenza A subtype cross-protection after immunization of outbred mice with a purified chimeric NS1/HA2 influenza virus protein.
Mbawuike IN; Dillion SB; Demuth SG; Jones CS; Cate TR; Couch RB
Vaccine; 1994 Nov; 12(14):1340-8. PubMed ID: 7856302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
